Latest Updates
Christer Rosén
September 19, 2025
Pre-ordering now available at Nugevia.com, shipping early October.
#Nugevia #Healthspan #Lifespan #Neuroprotection #Cognition #Mitochondria #JUNS
#Nugevia #Healthspan #Lifespan #Neuroprotection #Cognition #Mitochondria #JUNS
Read more
Jupiter Neurosciences, Inc.
September 19, 2025
As the Ryder Cup begins, we are proud to see golf legend Annika Sorenstam, our first official Brand Ambassador for Nugevia™, featured in the tournament magazine.
Marked by 95 international victories, Annika’s ability to compete at the highest level for decades is a powerful example of what Nugevia™ is designed to support: recovery, focus, and energy backed by real science. Built on our patented JOTROL™ platform, Nugevia™ supports cellular vitality and resilience — qualities essential not only for elite athletes but for anyone seeking to stay sharper, stronger, and healthier in life.
Partnering with Annika underscores our mission to put neuro health at the core of longevity, making science-backed wellness accessible while driving sustainable value for our consumers.
🧬 Learn more about Nugevia™: www.nugevia.com
Marked by 95 international victories, Annika’s ability to compete at the highest level for decades is a powerful example of what Nugevia™ is designed to support: recovery, focus, and energy backed by real science. Built on our patented JOTROL™ platform, Nugevia™ supports cellular vitality and resilience — qualities essential not only for elite athletes but for anyone seeking to stay sharper, stronger, and healthier in life.
Partnering with Annika underscores our mission to put neuro health at the core of longevity, making science-backed wellness accessible while driving sustainable value for our consumers.
🧬 Learn more about Nugevia™: www.nugevia.com
Read more
Jupiter Neurosciences, Inc.
September 27, 2025
Jupiter Neurosciences, Inc. (Nasdaq: JUNS) has opened patient enrollment in RESET, its Phase 2a study of JOTROL in Parkinson’s disease, with first dosing expected shortly.
Jupiter Neurosciences is a @b2idigital Featured Company. See the full profile: https://b2idigital.com/jupiter-neurosciences-1
Roughly 1.1 million Americans live with Parkinson’s disease, which still has no approved disease-modifying therapy. JOTROL is Jupiter’s enhanced-bioavailability resveratrol formulation, and RESET will evaluate its safety, tolerability, and pharmacokinetics in a randomized, placebo-controlled study.
Jupiter is also advancing a second CNS opportunity. The company signed a term sheet on May 20, 2026 for exclusive, perpetual U.S. rights to ALA-002, a next-generation psychedelic NCE from @pharmalabiotech8706 that would broaden its CNS-focused pipeline if the transaction closes.
Trial and pipeline highlights:
• RESET (NCT07592767) is enrolling 30 patients across study centers in DC, Maryland, and Virginia
• The 12-week study randomizes patients to two JOTROL doses or placebo, with completion projected for the first half of 2027
• Phase 1 work showed roughly 9-fold higher plasma bioavailability than conventional resveratrol, measurable cerebrospinal fluid levels, and no serious adverse events, supporting FDA IND clearance in November 2025
• The proposed ALA-002 rights would add a patented psychedelic NCE to Jupiter’s CNS and neuroinflammation pipeline
Christer Rosén, Chief Executive Officer of Jupiter Neurosciences, commented, “With enrollment now underway in the Phase 2a RESET trial we have reached a critical operational milestone. We look forward to generating the clinical data needed to evaluate JOTROL’s potential and to serve patients, providers, and the broader scientific community.”
See the press release: https://www.globenewswire.com/news-release/2026/05/27/3301824/0/en/jupiter-neurosciences-announces-patient-enrollment-underway-in-phase-2a-reset-trial-in-parkinson-s-disease.html
Jupiter Neurosciences, Inc. (Nasdaq: JUNS) is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. Its lead program, JOTROL, a proprietary enhanced-bioavailability resveratrol formulation, is in a Phase IIa clinical trial for Parkinson’s disease. JUNS also commercializes Nugevia, a consumer longevity supplement.
Jupiter Neurosciences is led by Christer Rosén, Founder, Chairman and CEO; Alison D. Silva, President and CBO; Saleem Elmasri, CPA, CFO; and Marshall Hayward, Ph.D., Co-Founder and CSO. Learn more at www.jupiterneurosciences.com and about other B2i Digital Featured Companies at https://b2idigital.com/featured-companies.
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted JUNS stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.
Jupiter Neurosciences is a @b2idigital Featured Company. See the full profile: https://b2idigital.com/jupiter-neurosciences-1
Roughly 1.1 million Americans live with Parkinson’s disease, which still has no approved disease-modifying therapy. JOTROL is Jupiter’s enhanced-bioavailability resveratrol formulation, and RESET will evaluate its safety, tolerability, and pharmacokinetics in a randomized, placebo-controlled study.
Jupiter is also advancing a second CNS opportunity. The company signed a term sheet on May 20, 2026 for exclusive, perpetual U.S. rights to ALA-002, a next-generation psychedelic NCE from @pharmalabiotech8706 that would broaden its CNS-focused pipeline if the transaction closes.
Trial and pipeline highlights:
• RESET (NCT07592767) is enrolling 30 patients across study centers in DC, Maryland, and Virginia
• The 12-week study randomizes patients to two JOTROL doses or placebo, with completion projected for the first half of 2027
• Phase 1 work showed roughly 9-fold higher plasma bioavailability than conventional resveratrol, measurable cerebrospinal fluid levels, and no serious adverse events, supporting FDA IND clearance in November 2025
• The proposed ALA-002 rights would add a patented psychedelic NCE to Jupiter’s CNS and neuroinflammation pipeline
Christer Rosén, Chief Executive Officer of Jupiter Neurosciences, commented, “With enrollment now underway in the Phase 2a RESET trial we have reached a critical operational milestone. We look forward to generating the clinical data needed to evaluate JOTROL’s potential and to serve patients, providers, and the broader scientific community.”
See the press release: https://www.globenewswire.com/news-release/2026/05/27/3301824/0/en/jupiter-neurosciences-announces-patient-enrollment-underway-in-phase-2a-reset-trial-in-parkinson-s-disease.html
Jupiter Neurosciences, Inc. (Nasdaq: JUNS) is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. Its lead program, JOTROL, a proprietary enhanced-bioavailability resveratrol formulation, is in a Phase IIa clinical trial for Parkinson’s disease. JUNS also commercializes Nugevia, a consumer longevity supplement.
Jupiter Neurosciences is led by Christer Rosén, Founder, Chairman and CEO; Alison D. Silva, President and CBO; Saleem Elmasri, CPA, CFO; and Marshall Hayward, Ph.D., Co-Founder and CSO. Learn more at www.jupiterneurosciences.com and about other B2i Digital Featured Companies at https://b2idigital.com/featured-companies.
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted JUNS stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.
Read more
B2i Digital, Inc.
May 27
Jupiter Neurosciences, Inc. (Nasdaq: JUNS) has opened patient enrollment in RESET, its Phase 2a study of JOTROL in Parkinson’s disease, with first dosing expected shortly.
Jupiter Neurosciences is a B2i Digital Featured Company. See the full profile: https://b2idigital.com/jupiter-neurosciences-1
Roughly 1.1 million Americans live with Parkinson’s disease, which still has no approved disease-modifying therapy. JOTROL is Jupiter’s enhanced-bioavailability resveratrol formulation, and RESET will evaluate its safety, tolerability, and pharmacokinetics in a randomized, placebo-controlled study.
Jupiter is also advancing a second CNS opportunity. The company signed a term sheet on May 20, 2026 for exclusive, perpetual U.S. rights to ALA-002, a next-generation psychedelic NCE from PharmAla Biotech that would broaden its CNS-focused pipeline if the transaction closes.
Trial and pipeline highlights:
• RESET (NCT07592767) is enrolling 30 patients across study centers in DC, Maryland, and Virginia
• The 12-week study randomizes patients to two JOTROL doses or placebo, with completion projected for the first half of 2027
• Phase 1 work showed roughly 9-fold higher plasma bioavailability than conventional resveratrol, measurable cerebrospinal fluid levels, and no serious adverse events, supporting FDA IND clearance in November 2025
• The proposed ALA-002 rights would add a patented psychedelic NCE to Jupiter’s CNS and neuroinflammation pipeline
Christer Rosén, Chief Executive Officer of Jupiter Neurosciences, commented, “With enrollment now underway in the Phase 2a RESET trial we have reached a critical operational milestone. We look forward to generating the clinical data needed to evaluate JOTROL’s potential and to serve patients, providers, and the broader scientific community.”
See the press release: https://www.globenewswire.com/news-release/2026/05/27/3301824/0/en/jupiter-neurosciences-announces-patient-enrollment-underway-in-phase-2a-reset-trial-in-parkinson-s-disease.html
Jupiter Neurosciences, Inc. (Nasdaq: JUNS) is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. Its lead program, JOTROL, a proprietary enhanced-bioavailability resveratrol formulation, is in a Phase IIa clinical trial for Parkinson’s disease. JUNS also commercializes Nugevia, a consumer longevity supplement.
Jupiter Neurosciences is led by Christer Rosén, Founder, Chairman and CEO; Alison D. Silva, President and CBO; Saleem Elmasri, CPA, CFO; and Marshall Hayward, Ph.D., Co-Founder and CSO. Learn more at www.jupiterneurosciences.com and about other B2i Digital Featured Companies at https://b2idigital.com/featured-companies.
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted JUNS stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.
Jupiter Neurosciences is a B2i Digital Featured Company. See the full profile: https://b2idigital.com/jupiter-neurosciences-1
Roughly 1.1 million Americans live with Parkinson’s disease, which still has no approved disease-modifying therapy. JOTROL is Jupiter’s enhanced-bioavailability resveratrol formulation, and RESET will evaluate its safety, tolerability, and pharmacokinetics in a randomized, placebo-controlled study.
Jupiter is also advancing a second CNS opportunity. The company signed a term sheet on May 20, 2026 for exclusive, perpetual U.S. rights to ALA-002, a next-generation psychedelic NCE from PharmAla Biotech that would broaden its CNS-focused pipeline if the transaction closes.
Trial and pipeline highlights:
• RESET (NCT07592767) is enrolling 30 patients across study centers in DC, Maryland, and Virginia
• The 12-week study randomizes patients to two JOTROL doses or placebo, with completion projected for the first half of 2027
• Phase 1 work showed roughly 9-fold higher plasma bioavailability than conventional resveratrol, measurable cerebrospinal fluid levels, and no serious adverse events, supporting FDA IND clearance in November 2025
• The proposed ALA-002 rights would add a patented psychedelic NCE to Jupiter’s CNS and neuroinflammation pipeline
Christer Rosén, Chief Executive Officer of Jupiter Neurosciences, commented, “With enrollment now underway in the Phase 2a RESET trial we have reached a critical operational milestone. We look forward to generating the clinical data needed to evaluate JOTROL’s potential and to serve patients, providers, and the broader scientific community.”
See the press release: https://www.globenewswire.com/news-release/2026/05/27/3301824/0/en/jupiter-neurosciences-announces-patient-enrollment-underway-in-phase-2a-reset-trial-in-parkinson-s-disease.html
Jupiter Neurosciences, Inc. (Nasdaq: JUNS) is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. Its lead program, JOTROL, a proprietary enhanced-bioavailability resveratrol formulation, is in a Phase IIa clinical trial for Parkinson’s disease. JUNS also commercializes Nugevia, a consumer longevity supplement.
Jupiter Neurosciences is led by Christer Rosén, Founder, Chairman and CEO; Alison D. Silva, President and CBO; Saleem Elmasri, CPA, CFO; and Marshall Hayward, Ph.D., Co-Founder and CSO. Learn more at www.jupiterneurosciences.com and about other B2i Digital Featured Companies at https://b2idigital.com/featured-companies.
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted JUNS stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.
Read more
B2i Digital
May 27
Jupiter Neurosciences, Inc. (Nasdaq: JUNS) announced the company has entered into a term sheet to acquire exclusive, perpetual U.S. licensing rights to ALA-002, the lead drug candidate of PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF). Under the term sheet, which the company describes as including up to $100 million in total potential consideration, Jupiter would make an upfront payment of $3.33 million, consisting of $1.5 million in cash and $1.83 million in JUNS common stock, with additional development milestone payments and single-digit royalties as the product is developed, approved, and commercialized.
Jupiter Neurosciences is a @b2idigital Featured Company. See the full profile: https://b2idigital.com/jupiter-neurosciences-1
ALA-002 is a patented, non-racemic MDMA formulation recognized by the FDA as a Novel Chemical Entity (NCE). It is engineered to potentially improve cardiovascular safety and reduce abuse liability versus racemic MDMA, while preserving the pro-social and therapeutic properties central to MDMA-assisted therapy.
Transaction and pipeline highlights:
• Exclusive, perpetual U.S. rights to a next-generation MDMA NCE that expands Jupiter's CNS-focused therapeutic pipeline
• PharmAla's MDMA supply is in active U.S. government-sponsored VA and DHA clinical trials
• Positioned within an emerging regulated U.S. psychedelic therapeutics market that analysts project could reach approximately $6 billion to $15 billion annually in the early-to-mid 2030s
• Timing follows the April 18, 2026 federal Executive Order directing the FDA and DEA to expand access to investigational psychedelic therapies
Christer Rosén, Chairman and Chief Executive Officer of Jupiter Neurosciences, commented, "This proposed transaction is strategically aligned with Jupiter's long-term focus on CNS innovation and the development of therapies intended to address longevity, brain health, neuroplasticity, and serious neuropsychiatric conditions."
D. Boral Capital, LLC is acting as sole financial advisor to Jupiter Neurosciences. The proposed transaction remains subject to due diligence, negotiation and execution of definitive agreements, and customary closing conditions.
See the press release: https://www.globenewswire.com/news-release/2026/05/20/3298378/0/en/jupiter-neurosciences-secures-100m-term-sheet-for-exclusive-u-s-rights-to-ala-002-a-next-generation-mdma-therapeutic-from-pharmala-biotech.html
Jupiter Neurosciences, Inc. (Nasdaq: JUNS) is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. Its lead program, JOTROL, a proprietary enhanced-bioavailability resveratrol formulation, is in a Phase IIa clinical trial for Parkinson's disease. JUNS also commercializes Nugevia, a consumer longevity supplement.
Jupiter Neurosciences is led by Christer Rosén, Founder, Chairman and CEO; Alison D. Silva, President and CBO; Saleem Elmasri, CPA, CFO; and Marshall Hayward, Ph.D., Co-Founder and CSO. Learn more at www.jupiterneurosciences.com and about other B2i Digital Featured Companies at https://b2idigital.com/featured-companies.
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted JUNS stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.
Jupiter Neurosciences is a @b2idigital Featured Company. See the full profile: https://b2idigital.com/jupiter-neurosciences-1
ALA-002 is a patented, non-racemic MDMA formulation recognized by the FDA as a Novel Chemical Entity (NCE). It is engineered to potentially improve cardiovascular safety and reduce abuse liability versus racemic MDMA, while preserving the pro-social and therapeutic properties central to MDMA-assisted therapy.
Transaction and pipeline highlights:
• Exclusive, perpetual U.S. rights to a next-generation MDMA NCE that expands Jupiter's CNS-focused therapeutic pipeline
• PharmAla's MDMA supply is in active U.S. government-sponsored VA and DHA clinical trials
• Positioned within an emerging regulated U.S. psychedelic therapeutics market that analysts project could reach approximately $6 billion to $15 billion annually in the early-to-mid 2030s
• Timing follows the April 18, 2026 federal Executive Order directing the FDA and DEA to expand access to investigational psychedelic therapies
Christer Rosén, Chairman and Chief Executive Officer of Jupiter Neurosciences, commented, "This proposed transaction is strategically aligned with Jupiter's long-term focus on CNS innovation and the development of therapies intended to address longevity, brain health, neuroplasticity, and serious neuropsychiatric conditions."
D. Boral Capital, LLC is acting as sole financial advisor to Jupiter Neurosciences. The proposed transaction remains subject to due diligence, negotiation and execution of definitive agreements, and customary closing conditions.
See the press release: https://www.globenewswire.com/news-release/2026/05/20/3298378/0/en/jupiter-neurosciences-secures-100m-term-sheet-for-exclusive-u-s-rights-to-ala-002-a-next-generation-mdma-therapeutic-from-pharmala-biotech.html
Jupiter Neurosciences, Inc. (Nasdaq: JUNS) is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. Its lead program, JOTROL, a proprietary enhanced-bioavailability resveratrol formulation, is in a Phase IIa clinical trial for Parkinson's disease. JUNS also commercializes Nugevia, a consumer longevity supplement.
Jupiter Neurosciences is led by Christer Rosén, Founder, Chairman and CEO; Alison D. Silva, President and CBO; Saleem Elmasri, CPA, CFO; and Marshall Hayward, Ph.D., Co-Founder and CSO. Learn more at www.jupiterneurosciences.com and about other B2i Digital Featured Companies at https://b2idigital.com/featured-companies.
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted JUNS stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.
Read more
B2i Digital, Inc.
May 20
Jupiter Neurosciences (Nasdaq: JUNS), a B2i Digital Featured Company, presents a live corporate update at the Emerging Growth Conference on June 10, 2026 at 2:20 PM ET, with a short Q&A to follow.
Jupiter is a clinical-stage biopharmaceutical company focused on the central nervous system and neuroinflammation, with a second path into the fast-growing consumer longevity market.
Jupiter Neurosciences is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/jupiter-neurosciences-1
The update caps one of the busiest runs in the company's history. A few things management is expected to walk through:
• A $100 million term sheet for exclusive U.S. rights to ALA-002, a next-generation MDMA therapeutic licensed from PharmAla Biotech, putting JUNS at the front of the U.S. psychedelic medicine space following the April 18 federal Executive Order opening access to investigational psychedelic therapies
• JOTROL, its lead program, an enhanced bioavailability resveratrol formulation now in a Phase IIa clinical trial for Parkinson's disease
• Nugevia, its revenue-generating consumer longevity line, available now at Nugevia.com
Register to attend:
https://goto.webcasts.com/starthere.jsp?ei=1757504&tp_key=cc5c9b4321&sti=juns
Jupiter Neurosciences is a clinical-stage biopharmaceutical company advancing JOTROL, a proprietary enhanced bioavailability resveratrol formulation, with a Phase IIa Parkinson's disease trial underway and a consumer longevity line, Nugevia. It trades on Nasdaq under JUNS.
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted JUNS stock, in line with B2i Digital's practice of investing alongside its Featured Companies. This post is informational only and is not an offer, solicitation, or recommendation regarding any security, and it does not offer any opinion on JUNS as an investment. Conduct your own research and consult your own professional advisors before making any investment decision. B2i Digital is not a broker-dealer or investment adviser. See the complete Disclosure at https://b2idigital.com/disclaimer.
Jupiter is a clinical-stage biopharmaceutical company focused on the central nervous system and neuroinflammation, with a second path into the fast-growing consumer longevity market.
Jupiter Neurosciences is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/jupiter-neurosciences-1
The update caps one of the busiest runs in the company's history. A few things management is expected to walk through:
• A $100 million term sheet for exclusive U.S. rights to ALA-002, a next-generation MDMA therapeutic licensed from PharmAla Biotech, putting JUNS at the front of the U.S. psychedelic medicine space following the April 18 federal Executive Order opening access to investigational psychedelic therapies
• JOTROL, its lead program, an enhanced bioavailability resveratrol formulation now in a Phase IIa clinical trial for Parkinson's disease
• Nugevia, its revenue-generating consumer longevity line, available now at Nugevia.com
Register to attend:
https://goto.webcasts.com/starthere.jsp?ei=1757504&tp_key=cc5c9b4321&sti=juns
Jupiter Neurosciences is a clinical-stage biopharmaceutical company advancing JOTROL, a proprietary enhanced bioavailability resveratrol formulation, with a Phase IIa Parkinson's disease trial underway and a consumer longevity line, Nugevia. It trades on Nasdaq under JUNS.
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted JUNS stock, in line with B2i Digital's practice of investing alongside its Featured Companies. This post is informational only and is not an offer, solicitation, or recommendation regarding any security, and it does not offer any opinion on JUNS as an investment. Conduct your own research and consult your own professional advisors before making any investment decision. B2i Digital is not a broker-dealer or investment adviser. See the complete Disclosure at https://b2idigital.com/disclaimer.
Read more
B2i Digital
2 days ago
Jupiter Neurosciences, Inc. (Nasdaq: JUNS) announced the company has entered into a term sheet to acquire exclusive, perpetual U.S. licensing rights to ALA-002, the lead drug candidate of PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF). Under the term sheet, which the company describes as including up to $100 million in total potential consideration, Jupiter would make an upfront payment of $3.33 million, consisting of $1.5 million in cash and $1.83 million in JUNS common stock, with additional development milestone payments and single-digit royalties as the product is developed, approved, and commercialized.
Jupiter Neurosciences is a B2i Digital Featured Company. See the full profile: https://b2idigital.com/jupiter-neurosciences-1
ALA-002 is a patented, non-racemic MDMA formulation recognized by the FDA as a Novel Chemical Entity (NCE). It is engineered to potentially improve cardiovascular safety and reduce abuse liability versus racemic MDMA, while preserving the pro-social and therapeutic properties central to MDMA-assisted therapy.
Transaction and pipeline highlights:
• Exclusive, perpetual U.S. rights to a next-generation MDMA NCE that expands Jupiter's CNS-focused therapeutic pipeline
• PharmAla's MDMA supply is in active U.S. government-sponsored VA and DHA clinical trials
• Positioned within an emerging regulated U.S. psychedelic therapeutics market that analysts project could reach approximately $6 billion to $15 billion annually in the early-to-mid 2030s
• Timing follows the April 18, 2026 federal Executive Order directing the FDA and DEA to expand access to investigational psychedelic therapies
Christer Rosén, Chairman and Chief Executive Officer of Jupiter Neurosciences, commented, "This proposed transaction is strategically aligned with Jupiter's long-term focus on CNS innovation and the development of therapies intended to address longevity, brain health, neuroplasticity, and serious neuropsychiatric conditions."
D. Boral Capital, LLC is acting as sole financial advisor to Jupiter Neurosciences. The proposed transaction remains subject to due diligence, negotiation and execution of definitive agreements, and customary closing conditions.
See the press release: https://www.globenewswire.com/news-release/2026/05/20/3298378/0/en/jupiter-neurosciences-secures-100m-term-sheet-for-exclusive-u-s-rights-to-ala-002-a-next-generation-mdma-therapeutic-from-pharmala-biotech.html
Jupiter Neurosciences, Inc. (Nasdaq: JUNS) is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. Its lead program, JOTROL, a proprietary enhanced-bioavailability resveratrol formulation, is in a Phase IIa clinical trial for Parkinson's disease. JUNS also commercializes Nugevia, a consumer longevity supplement.
Jupiter Neurosciences is led by Christer Rosén, Founder, Chairman and CEO; Alison D. Silva, President and CBO; Saleem Elmasri, CPA, CFO; and Marshall Hayward, Ph.D., Co-Founder and CSO. Learn more at www.jupiterneurosciences.com and about other B2i Digital Featured Companies at https://b2idigital.com/featured-companies.
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted JUNS stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.
Jupiter Neurosciences is a B2i Digital Featured Company. See the full profile: https://b2idigital.com/jupiter-neurosciences-1
ALA-002 is a patented, non-racemic MDMA formulation recognized by the FDA as a Novel Chemical Entity (NCE). It is engineered to potentially improve cardiovascular safety and reduce abuse liability versus racemic MDMA, while preserving the pro-social and therapeutic properties central to MDMA-assisted therapy.
Transaction and pipeline highlights:
• Exclusive, perpetual U.S. rights to a next-generation MDMA NCE that expands Jupiter's CNS-focused therapeutic pipeline
• PharmAla's MDMA supply is in active U.S. government-sponsored VA and DHA clinical trials
• Positioned within an emerging regulated U.S. psychedelic therapeutics market that analysts project could reach approximately $6 billion to $15 billion annually in the early-to-mid 2030s
• Timing follows the April 18, 2026 federal Executive Order directing the FDA and DEA to expand access to investigational psychedelic therapies
Christer Rosén, Chairman and Chief Executive Officer of Jupiter Neurosciences, commented, "This proposed transaction is strategically aligned with Jupiter's long-term focus on CNS innovation and the development of therapies intended to address longevity, brain health, neuroplasticity, and serious neuropsychiatric conditions."
D. Boral Capital, LLC is acting as sole financial advisor to Jupiter Neurosciences. The proposed transaction remains subject to due diligence, negotiation and execution of definitive agreements, and customary closing conditions.
See the press release: https://www.globenewswire.com/news-release/2026/05/20/3298378/0/en/jupiter-neurosciences-secures-100m-term-sheet-for-exclusive-u-s-rights-to-ala-002-a-next-generation-mdma-therapeutic-from-pharmala-biotech.html
Jupiter Neurosciences, Inc. (Nasdaq: JUNS) is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. Its lead program, JOTROL, a proprietary enhanced-bioavailability resveratrol formulation, is in a Phase IIa clinical trial for Parkinson's disease. JUNS also commercializes Nugevia, a consumer longevity supplement.
Jupiter Neurosciences is led by Christer Rosén, Founder, Chairman and CEO; Alison D. Silva, President and CBO; Saleem Elmasri, CPA, CFO; and Marshall Hayward, Ph.D., Co-Founder and CSO. Learn more at www.jupiterneurosciences.com and about other B2i Digital Featured Companies at https://b2idigital.com/featured-companies.
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted JUNS stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.
Read more
B2i Digital
May 20
Jupiter Neurosciences (@nasdaq: JUNS) a @b2idigital Featured Company, presents a live corporate update at the Emerging Growth Conference on June 10, 2026 at 2:20 PM ET, with a short Q&A to follow.
Jupiter is a clinical-stage biopharmaceutical company focused on the central nervous system and neuroinflammation, with a second path into the fast-growing consumer longevity market.
Jupiter Neurosciences is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/jupiter-neurosciences-1
The update caps one of the busiest runs in the company's history. A few things management is expected to walk through:
• A $100 million term sheet for exclusive U.S. rights to ALA-002, a next-generation MDMA therapeutic licensed from @pharmalabiotech8706, putting JUNS at the front of the U.S. psychedelic medicine space following the April 18 federal Executive Order opening access to investigational psychedelic therapies
• JOTROL, its lead program, an enhanced bioavailability resveratrol formulation now in a Phase IIa clinical trial for Parkinson's disease
• @Nugevialife, its revenue-generating consumer longevity line, available now at Nugevia.com
Register to attend:
https://goto.webcasts.com/starthere.jsp?ei=1757504&tp_key=cc5c9b4321&sti=juns
Jupiter Neurosciences is a clinical-stage biopharmaceutical company advancing JOTROL, a proprietary enhanced bioavailability resveratrol formulation, with a Phase IIa Parkinson's disease trial underway and a consumer longevity line, Nugevia. It trades on Nasdaq under JUNS.
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted JUNS stock, in line with B2i Digital's practice of investing alongside its Featured Companies. This post is informational only and is not an offer, solicitation, or recommendation regarding any security, and it does not offer any opinion on JUNS as an investment. Conduct your own research and consult your own professional advisors before making any investment decision. B2i Digital is not a broker-dealer or investment adviser. See the complete Disclosure at https://b2idigital.com/disclaimer.
Jupiter is a clinical-stage biopharmaceutical company focused on the central nervous system and neuroinflammation, with a second path into the fast-growing consumer longevity market.
Jupiter Neurosciences is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/jupiter-neurosciences-1
The update caps one of the busiest runs in the company's history. A few things management is expected to walk through:
• A $100 million term sheet for exclusive U.S. rights to ALA-002, a next-generation MDMA therapeutic licensed from @pharmalabiotech8706, putting JUNS at the front of the U.S. psychedelic medicine space following the April 18 federal Executive Order opening access to investigational psychedelic therapies
• JOTROL, its lead program, an enhanced bioavailability resveratrol formulation now in a Phase IIa clinical trial for Parkinson's disease
• @Nugevialife, its revenue-generating consumer longevity line, available now at Nugevia.com
Register to attend:
https://goto.webcasts.com/starthere.jsp?ei=1757504&tp_key=cc5c9b4321&sti=juns
Jupiter Neurosciences is a clinical-stage biopharmaceutical company advancing JOTROL, a proprietary enhanced bioavailability resveratrol formulation, with a Phase IIa Parkinson's disease trial underway and a consumer longevity line, Nugevia. It trades on Nasdaq under JUNS.
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted JUNS stock, in line with B2i Digital's practice of investing alongside its Featured Companies. This post is informational only and is not an offer, solicitation, or recommendation regarding any security, and it does not offer any opinion on JUNS as an investment. Conduct your own research and consult your own professional advisors before making any investment decision. B2i Digital is not a broker-dealer or investment adviser. See the complete Disclosure at https://b2idigital.com/disclaimer.
Read more
B2i Digital, Inc.
2 days ago
Tomorrow marks a milestone for Jupiter Neurosciences. We will light up Nasdaq Times Square to share our mission of putting neuro health at the core of longevity and celebrate the official launch of our Nugevia™ nutraceutical line at Rockefeller Center in New York City.
This moment reflects our commitment to bringing decades of CNS research into everyday health, and to sharing that vision on a global stage.
🧬 Learn more about Nugevia™: www.nugevia.com
#Nugevia #Neuroprotection #HealthyAging #Neuroscience #Longevity #JUNS
This moment reflects our commitment to bringing decades of CNS research into everyday health, and to sharing that vision on a global stage.
🧬 Learn more about Nugevia™: www.nugevia.com
#Nugevia #Neuroprotection #HealthyAging #Neuroscience #Longevity #JUNS
Read more
Jupiter Neurosciences, Inc.
September 24, 2025
Our Founder, Chairman & CEO Christer Rosén recently joined Planning Alternatives' Day in a Canoe Podcast to share Jupiter’s journey.
He spoke about his path as a serial entrepreneur, from computer science to biotech innovation, and how Jupiter is redefining neuro health as the foundation of longevity.
In the conversation, he reflected on our patented JOTROL™ resveratrol delivery platform – shown in Phase I trials to reach over 9× higher bioavailability – and how it inspired the creation of Nugevia™, a nutraceutical line designed to translate decades of CNS research into everyday wellness.
Tune in to the full conversation here:
🎧Apple Podcasts: https://lnkd.in/ggCatNGe
🎧Spotify: https://lnkd.in/gthuXqGt
#Nugevia #Neuroprotection #Neuroscience #Longevity #JUNS
He spoke about his path as a serial entrepreneur, from computer science to biotech innovation, and how Jupiter is redefining neuro health as the foundation of longevity.
In the conversation, he reflected on our patented JOTROL™ resveratrol delivery platform – shown in Phase I trials to reach over 9× higher bioavailability – and how it inspired the creation of Nugevia™, a nutraceutical line designed to translate decades of CNS research into everyday wellness.
Tune in to the full conversation here:
🎧Apple Podcasts: https://lnkd.in/ggCatNGe
🎧Spotify: https://lnkd.in/gthuXqGt
#Nugevia #Neuroprotection #Neuroscience #Longevity #JUNS
Read more
Jupiter Neurosciences, Inc.
September 24, 2025
